Rheumatology Medical News about Ibandronate, Osteoporosis, Bone marker

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women
International Journal of Rheumatic Diseases, 08/19/09

The BONADASIA study group – The Asian postmenopausal osteoporosis patients in this study had a high adherence rate to once-monthly ibandronate therapy. Use of serum carboxy-terminal collagen crosslinks (CTX) bone marker feedback (BMF) had no further impact on increasing adherence, but increased treatment satisfaction.

Methods

Study to assess the impact of serum CTX BMF on adherence to ibandronate treatment in Asian postmenopausal women with osteoporosis
A 12-mo (6-monthly phased), trial conducted in 596 (of 628 enrolled) pts (≤85 yrs old) who were naïve, lapsed, or current bisphosphonate users
Pts were randomized into 2 arms: serum CTX BMF at 3 mo vs no-BMF
Once-monthly 150 mg ibandronate tablet was administered for 12 mo and adherence to therapy was assessed at 6 and 12 mo
In addition, patient satisfaction and safety of ibandronate treatment were also assessed

Results

Serum CTX BMF at 3 mo showed no impact on adherence
Proportions of adherent pts were comparable in the BMF vs no-BMF arms
Overall, serum CTX levels were similar for adherent and non-adherent pts
However, BMF pts felt more informed about their osteoporosis and more satisfied than no-BMF pts

<< Previous
Genome-wide copy number variation association study suggested...

Next >>
Does prolonged systemic glucocorticoid use increase risk of...